IL286283A - Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics - Google Patents

Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Info

Publication number
IL286283A
IL286283A IL286283A IL28628321A IL286283A IL 286283 A IL286283 A IL 286283A IL 286283 A IL286283 A IL 286283A IL 28628321 A IL28628321 A IL 28628321A IL 286283 A IL286283 A IL 286283A
Authority
IL
Israel
Prior art keywords
pah
viral dna
dna vectors
phenylalanine hydroxylase
therapeutic expression
Prior art date
Application number
IL286283A
Other languages
English (en)
Hebrew (he)
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of IL286283A publication Critical patent/IL286283A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL286283A 2019-03-13 2021-09-12 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics IL286283A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817771P 2019-03-13 2019-03-13
US201962857514P 2019-06-05 2019-06-05
PCT/US2020/022595 WO2020186150A2 (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Publications (1)

Publication Number Publication Date
IL286283A true IL286283A (en) 2021-10-31

Family

ID=72426457

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286283A IL286283A (en) 2019-03-13 2021-09-12 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Country Status (12)

Country Link
US (1) US12415002B2 (https=)
EP (1) EP3938515A4 (https=)
JP (2) JP7583732B2 (https=)
KR (1) KR20210149702A (https=)
CN (1) CN113874508A (https=)
AU (1) AU2020235121A1 (https=)
BR (1) BR112021017852A2 (https=)
CA (1) CA3133330A1 (https=)
IL (1) IL286283A (https=)
MX (1) MX2021011037A (https=)
SG (1) SG11202109830TA (https=)
WO (1) WO2020186150A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4165196A1 (en) * 2020-06-11 2023-04-19 Sangamo Therapeutics, Inc. Methods and compositions for expressing phenylalanine hydroxylase
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
EP4214309A4 (en) * 2020-09-16 2025-07-16 Generation Bio Co CLOSED-END DNA VECTORS AND RELATED USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH)
GB202014751D0 (en) * 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
MX2023003805A (es) 2020-10-01 2023-04-12 Genzyme Corp Casete de expresion de pah humana para el tratamiento de la pku mediante terapia de reemplazo genico dirigida al higado.
CN115772503B (zh) * 2022-08-16 2023-10-17 广东省南山医药创新研究院 一种表达pah的基因修饰细胞药物及其制备方法与应用
AU2024257493A1 (en) * 2023-04-18 2025-12-04 Siren Biotechnology, Inc. Adeno-associated viral vector compositions and methods of use
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用
CN119876192B (zh) * 2024-07-02 2025-11-07 浙江大学滨江研究院 用于治疗苯丙酮尿症的多核苷酸

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535877T3 (es) 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
MX2018010633A (es) 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
KR102738752B1 (ko) 2016-12-30 2024-12-06 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 페닐케톤뇨증을 치료하기 위한 유전자 치료
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
US11820999B2 (en) * 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
EP3630200A4 (en) 2017-05-31 2021-02-24 Arcturus Therapeutics, Inc. THERAPEUTICS FOR PHENYLKETONURIA
NZ762100A (en) * 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
KR20210149702A (ko) 2021-12-09
EP3938515A2 (en) 2022-01-19
JP2022525302A (ja) 2022-05-12
CN113874508A (zh) 2021-12-31
CA3133330A1 (en) 2020-09-17
WO2020186150A3 (en) 2020-10-29
JP2025016685A (ja) 2025-02-04
EP3938515A4 (en) 2022-12-28
BR112021017852A2 (pt) 2021-11-30
JP7583732B2 (ja) 2024-11-14
SG11202109830TA (en) 2021-10-28
WO2020186150A2 (en) 2020-09-17
MX2021011037A (es) 2021-12-15
AU2020235121A1 (en) 2021-11-04
US12415002B2 (en) 2025-09-16
US20230024354A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
IL286283A (en) Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics
EP3458585A4 (en) GENE THERAPY PROCEDURES FOR AGE-RELATED ILLNESSES AND SUFFERING
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
EA202192815A1 (ru) Опосредуемая aav-вектором делеция крупной мутационной "горячей точки" для лечения мышечной дистрофии дюшенна
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
IL280636A (en) Alternative splicing regulation of gene expression and therapeutic methods
HRP20260212T1 (hr) Pripravci i postupci za liječenje mišićne distrofije
MA50096A (fr) Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
IL290792A (en) Compositions and methods for the treatment of viral infections
EA201891317A3 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
IL290132A (en) Materials and methods for treating friedreich's ataxia
MA46111A (fr) Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci
IL292460A (en) Huntingtin (htt) irna agent compositions and methods of use thereof
IL286811A (en) Compositions and methods for stabilizing protein-containing formulations
EP3762407A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH ECM AFFINITY PEPTIDES BONDED TO CYTOKINE
EP3980067A4 (en) ANTIBODY INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
EP3723739A4 (en) PARASITICIDAL ISOXAZOLINE FORMULATIONS AND METHODS OF TREATMENT OF BLEPHARITIS
IL281577A (en) Compositions and methods for treating retinitis pigmentosa
IL290817A (en) Methods for production of human recombinant arginase 1 and uses thereof
EP3773500A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
EP4308173A4 (en) NON-VIRAL DNA VECTORS AND THEIR USES FOR EXPRESSING PFIC THERAPEUTIC AGENTS
EP4402267A4 (en) Liver-specific expression cassettes, vectors, and their uses for expressing therapeutic proteins
EP4214309A4 (en) CLOSED-END DNA VECTORS AND RELATED USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH)
IL291351A (en) Compositions for the treatment of solid tumors